Chronic Fatigue Syndrome Clinical Trial
Official title:
Use of Lisdexamfetamine Dimesylate in Treatment of Cognitive Impairment (Chronic Fatigue Syndrome): A Double Blind, Placebo Controlled Study
Over the past decade, the Rochester Center for Behavioral Medicine (RCBM) has evaluated many
patients with attention deficit hyperactivity disorder (ADHD). A recurrent finding in these
patients is a history of unexplained fatigue and musculoskeletal pain.
Treatment of these patients in our clinic has revealed that when their underlying ADHD is
treated with psychostimulant medication, many patients report significant improvements with
regard to their fatigue and musculoskeletal pain. Patients report less subjective fatigue
and pain and note overall functional improvement, although the initial and primary objective
was the treatment of their attention or hyperactivity problems. We speculate that stimulants
are efficacious by offering two distinct clinical properties. 1) anti-fatigue properties and
2) properties that allow patients to filter out extraneous stimuli (i.e. chronic muscle
pain).
As a result of these findings RCBM developed a chronic fatigue/fibromyalgia clinic in the
early 2000's. This clinic was staffed by a board-certified rheumatologist and the
psychiatric staff at RCBM. Through the major referral hospital in the area, patients with
self-identified fibromyalgia and chronic fatigue were referred to our clinic. Over eighteen
months, we evaluated 75 patients, and found that in patients who had comprehensive
evaluations, nearly 70 percent also had a history of ADHD, inattentive or combined types.
Diagnosis was made using clinical history and standardized symptom checklists. Oftentimes,
the ADHD had been previously undiagnosed. This finding supports the link between ADHD and
FMS/CFS.
Results from these evaluations reinforced our initial findings: patients who are treated for
their ADHD symptoms also show a reduction in their chronic pain and fatigue symptoms. This
is true regardless of previous (unsuccessful) therapies to treat their fibromyalgia.
As a result of these findings, we are conducting a controlled study to further demonstrate
the efficacy of lisdexamfetamine dimesylate (LDX) in controlling fatigue symptoms in
patients presenting with chronic fatigue syndrome. This is a double-blind,
placebo-controlled study over a period of 8 weeks, where subjects are randomized to either
LDX or placebo. We will evaluate subjects through standardized pain, fatigue and ADHD
assessment scales.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05454683 -
Melatonin and Zinc Administration on Cardinal Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
|
N/A | |
Completed |
NCT01686074 -
Motor Control in Chronic Fatigue Syndrome and Fibromyalgia
|
N/A | |
Completed |
NCT02075489 -
Acupressure for Pain Management and Fatigue Relief in Gulf War Veterans
|
N/A | |
Completed |
NCT01651754 -
Humoral and Cellular Immune Responses After Influenza Vaccination in Patients With Postcancer Fatigue and in Patients With Chronic Fatigue Syndrome
|
N/A | |
Completed |
NCT00540254 -
Behavioral Insomnia Therapy With Chronic Fatigue Syndrome
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00071162 -
Genetics of Fibromyalgia
|
N/A | |
Withdrawn |
NCT04870476 -
Feasibility and Acceptability of the Internet-delivered Treatment "One Step at the Time" for Bodily Distress Syndrome
|
N/A | |
Completed |
NCT05730660 -
Quercetin Phytosome® Chronic Fatigue Syndrome
|
N/A | |
Recruiting |
NCT04542161 -
Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
|
Phase 2 | |
Recruiting |
NCT03807973 -
Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.
|
Phase 1 | |
Recruiting |
NCT05719493 -
Effectiveness and Health Benefits of a Nutritional, Chronobiological and Physical Exercise Intervention in Fibromyalgia and Chronic Fatigue Syndrome (SYNCHRONIZE +)
|
N/A | |
Recruiting |
NCT05967052 -
Investigation of Treating Chronic Fatigue Syndrome After COVID With Pharmacotherapy (Pregabalin) or Complex Rehabilitation
|
Phase 2 | |
Terminated |
NCT01730495 -
Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome
|
Phase 2 | |
Completed |
NCT01156909 -
B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome
|
Phase 2 | |
Completed |
NCT01650636 -
Patient-Partner Stress Management Effects on Chronic Fatigue Syndrome Symptoms and Neuroimmune Process
|
N/A | |
Completed |
NCT01046370 -
A Pilot Study of Amygdala Retraining Program in Patients With Chronic Fatigue Syndrome, Chronic Fatigue and Fibromyalgia
|
N/A | |
Completed |
NCT00100412 -
Hyporeactivity and Gulf War Illness
|
N/A | |
Recruiting |
NCT06128967 -
A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial
|
Phase 3 | |
Completed |
NCT02669212 -
Myalgic Encephalomyelitis Chronic Fatigue at the National Institutes of Health
|
N/A | |
Not yet recruiting |
NCT06011135 -
Exploring Worry in CFS/ME
|